Casey McDonald

The populist-driven shifts trumpeted from the US to the EU leaves plenty of question marks when trying to size up the trajectory of the global pharma industry. One certainty, however, will be change.

Rethinking views on limited-efficacy drug approvals may be in order.

Cleveland Clinic looks at the big medical innovations in store for 2017.

The industry is readying for a leap into a new age of complex therapies, as new heights are reached in fields such as regenerative cell-based therapies, CAR-T and immuno-oncology combinations. Elaborate manufacturing and soaring drug costs, however, loom as deep chasms to cross in bridging the potential with reality.

Today’s C-suite executives in the life sciences must be experts in many disciplines. Pharm Exec examines the evolving role of the chief financial officer as not just a numbers and bottom-line risk manager but an integral contributor to overall corporate strategy and close partner to the CEO.

When lobbying tips the scales: a path to drug approval.

Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation

Vice President, US Payer & Institutional Strategy Lead, Shire

Vice President, Business Development, Regeneron Pharmaceuticals

Senior Director, Marketing, XenoPort